Novo Nordisk

Price has completed a full corrective structure (A–B–C) after a strong multi-year bullish cycle.

Current levels show price stabilizing inside a major demand zone (38–42 EUR).

Long-term structure suggests the correction may be near completion, preparing for the next macro wave (potential Wave C continuation to the upside).

Novo Nordisk B

Novo Nordisk is a global pharmaceutical leader specializing in diabetes care, obesity treatments, and chronic disease medicine. Known for pioneering insulin innovation and blockbuster drugs like Ozempic and Wegovy, the company has become one of Europe’s most influential healthcare giants.

With expanding demand for metabolic treatments and a robust research pipeline, Novo Nordisk continues to position itself as a dominant player in long-term health and biotech innovation.

Monthly

Weekly